EVOKE PHARMA, INC. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3db99a5b-ee6f-4081-a901-a78467157e60/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-5.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038712 |
| FY 2023 | $-7.4M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-031435 |
| FY 2022 | $-7.8M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008942 |
| FY 2021 | $-8.2M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009118 |
| FY 2020 | $-13.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012510 |
| FY 2019 | $-7.2M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010254 |
| FY 2018 | $-8.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006404 |
| FY 2017 | $-11.2M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004725 |
| FY 2016 | $-10.5M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004426 |
| FY 2015 | $-11.8M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014408 |
| FY 2014 | $-13.2M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001287 |
| FY 2013 | $-25.5M | 2007-01-30 – 2014-03-31 | evidence 0001193125-14-197023 |
| FY 2012 | $-2.0M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-114409 |
| FY 2011 | $-2.4M | 2011-01-01 – 2011-12-31 | evidence 0001193125-14-114409 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).